A Phase 3 interventional study of Trazodone Hydrochloride (HCl) Extended-Release Tablets and Placebo in Major Depressive Disorder, sponsored by Labopharm Inc.. Completed at 37 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-27.
Sponsored by Labopharm Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 185th largest by enrollment of the 1,323 interventional ones that give a count, is one of 50 that started in 2007, is one of 240 in phase 3, and was the 315th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 22–60
Baylor College of Medicine · Sites in United States
Ages 18–64
Ohio State University · Sites in United States
Ages 21–65
Florida State University · Sites in United States
Ages 18–55 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,500 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 135 · Phase 2 325 · Phase 3 262 · Phase 4 189
First in 1979; this study’s year is marked. 50 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 412 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 70 across the 1,323 interventional studies, 100 across the 171 observational. Of the 1,156 that completed or were terminated, 584 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
484 of 1,500 have an industry lead sponsor. The 10 most frequent:
Labopharm Inc. is the lead sponsor of 19 studies on the registry; none are open to participants now.
Labopharm Inc. has 1 study filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
99 of the studies in Depressive Disorder, Major with a site in United States that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
| NCT06922110Phase 3Xenon Pharmaceuticals Inc.An Open-Label Study of Azetukalner in Major Depressive Disorder | 2027-01 |
| NCT04041479Phase 3Weill Medical College of Cornell UniversityBiomarker-guided rTMS for Treatment Resistant Depression | 2027-04 |
| NCT05850689Phase 3Intra-Cellular Therapies, Inc.Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | 2027-04-05 |
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
Add all 99 to your calendar (.ics) → With an account.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to demonstrate efficacy, safety and clinical benefit of Trazodone Contramid® OAD (Once A Day) in the treatment of Unipolar Major Depressive Disorder (MDD).
This two-arm, multicentre, randomized, placebo-controlled, double-blind, parallel-design study consisted of a baseline phase (screening and wash-out) and a double-blind randomized phase (randomization to Trazodone Contramid® OAD or placebo). The total study duration including wash-out of prohibited medications was approximately 11 weeks; the total duration of the randomized phase was 8 weeks (titration: 2 weeks + treatment: 6 weeks).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Use of the following concomitant treatment during the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Trazodone Hydrochloride (HCl) Extended-Release Tablets
Drug: Placebo
Also known as: Oleptro
Change in Hamilton Depression Scale (HAMD-17) Total Score From Baseline
The Hamilton Depression Rating Scale 17 items \[HAMD-17\] is a 17-item scale that evaluates depressed mood, vegetative and cognitive symptoms of depression, and co-morbid anxiety symptoms. The 17 items are rated on either a 5-point (0-4) or a 3-point (0-2) scale. In general, the 5 point scale items use a rating of 0=absent; 1=doubtful to mild; 2=mild to moderate; 3=moderate to severe; 4=very severe. The 3-point scale items use a rating of 0=absent; 1=probable or mild; 2=definite. The total HAMD-17score ranges from 0 (not ill) to 52 (severely ill).
Time frame: Baseline to Week 8
HAMD-17 Responders at Each Visit
Number of patients who show a response (defined as at least a 50% reduction from baseline in HAMD-17 score) at each post-baseline visit.
Time frame: Weeks 1, 2, 3, 4, 6, 8
HAMD-17 Remitters at Each Visit
Number of patients who are remitters (defined as patients who achieved a HAMD-17 total score ≤7) at each post-baseline visit.
Time frame: Weeks 1, 2, 3, 4, 6, 8
Change in HAMD-17 Depressed Mood Item (Item 1) Score From Baseline to Each Visit
Change from baseline in the HAMD-17, item 1: Depressed Mood item, at each post-baseline visit. The Depressed Mood item is rated on a 5-point scale ranging from rating of 0=absent; to 4=very severe.
Time frame: Baseline to Weeks 1, 2, 3, 4, 6, 8
Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score From Baseline
The Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10 item clinician-administered depression rating scale. The 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts) are rated on a scale ranging from 0 (low severity/difficulty) to 6 (high severity/difficulty) with anchors at 2-point intervals. The overall total score range is from 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
Time frame: Baseline to Week 8
Change From Baseline in Clinical Global Impression of Severity (CGI-S) to Each Visit
The CGI-Severity (CGI-S) consists of one question for the investigator: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on the following seven-point scale: 1=normal, not ill at all; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.
Time frame: Baseline to Weeks 1, 2, 3, 4, 6, 8
Clinical Global Impression - Improvement of Illness (CGI-I) Score at Last Study Visit
The CGI-Improvement of Illness (CGI-I) consists of one question for the investigator: "Compared to his condition at the start of the study, how much has this patient changed?" which is rated on the following seven-point scale 1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; 7=very much worse.
Time frame: Week 8
Patient Global Impression - Improvement of Illness (PGI-I) Score at Last Study Visit
The PGI-Improvement of Illness (PGI-I) consists of one question for the patient: "Since the start of the study, my overall status with regard to depression is?" which is rated on the following seven-point scale 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6= much worse; 7=very much worse.
Time frame: Week 8
Clinical Global Impression - Improvement of Illness (CGI-I) Responders at Last Study Visit
Patients were responders if the CGI-I rating was "Much Improved" or "Very Much Improved". The CGI-Improvement of Illness (CGI-I) consists of one question for the investigator: "Compared to his condition at the start of the study, how much has this patient changed?" which is rated on the following seven-point scale 1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; 7=very much worse. Results are expressed in number of patients.
Time frame: Week 8
Patient Global Impression - Improvement of Illness (PGI-I) Responders at Last Study Visit
Patients were responders if the PGI-I rating was "Much Improved" or "Very Much Improved". The PGI-Improvement of Illness (PGI-I) consists of one question for the patient: "Since the start of the study, my overall status with regard to depression is?" which is rated on the following seven-point scale 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6= much worse; 7=very much worse. Results are expressed in number of patients.
Time frame: Week 8
Overall Quality of Sleep at Each Visit
Overall Quality of Sleep was measured on a 4-point rating scale ranging from 1 = very poor to 4 = excellent in response to the question: "Since the last study visit, how would you rate the overall quality of your sleep?".
Time frame: Weeks 1, 2, 3, 4, 6, 8
Trouble Falling Asleep at Each Visit
Trouble Falling Asleep was measured on a 4-point rating scale ranging from 1 = never to 4 = always in response to the question: "Since the last study visit, how often did you experience trouble falling asleep?".
Time frame: Weeks 1, 2, 3, 4, 6, 8
Awakening During the Night at Each Visit
Awakening during the night was measured on a 4-point rating scale ranging from 1 = never to 4 = always in response to the question: "Since the last study visit did you awaken during the night?".
Time frame: Weeks 1, 2, 3, 4, 6, 8
Discontinuation Due to Lack of Efficacy
Number of patients who discontinued due to lack of efficacy during the whole study period (8 weeks).
Time frame: Baseline to Week 8
| Milestone | Trazodone Contramid OAD | Placebo |
|---|---|---|
| Started | 206 | 206 |
| Received study medication | 202 | 204 |
| Completed | 144 | 163 |
| Not completed | 62 | 43 |
| Withdrew: Adverse event | 25 | 6 |
| Withdrew: Lack of efficacy | 8 | 9 |
| Withdrew: Withdrawal by subject | 11 | 9 |
| Withdrew: Lost to follow-up | 11 | 15 |
| Withdrew: Administrative reason | 2 | 0 |
| Withdrew: Noncompliance | 4 | 2 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Entered other study | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 |
The Hamilton Depression Rating Scale 17 items \[HAMD-17\] is a 17-item scale that evaluates depressed mood, vegetative and cognitive symptoms of depression, and co-morbid anxiety symptoms. The 17 items are rated on either a 5-point (0-4) or a 3-point (0-2) scale. In general, the 5 point scale items use a rating of 0=absent; 1=doubtful to mild; 2=mild to moderate; 3=moderate to severe; 4=very severe. The 3-point scale items use a rating of 0=absent; 1=probable or mild; 2=definite. The total HAMD-17score ranges from 0 (not ill) to 52 (severely ill).
| Points on HAMD-17 scale | Trazodone Contramid OAD | Placebo |
|---|---|---|
| Baseline | 23.2 ± 4.16 | 22.4 ± 4.43 |
| Week 8 or LOCF | 11.8 ± 7.99 | 13.2 ± 8.06 |
| Change from baseline | -11.4 ± 8.20 | -9.3 ± 7.94 |
Number of patients who show a response (defined as at least a 50% reduction from baseline in HAMD-17 score) at each post-baseline visit.
| Participants | Trazodone Contramid OAD | Placebo |
|---|---|---|
| ≥50% reduction in HAMD-17 at Week 1 (n=197, n=199) | 25 | 19 |
| ≥50% reduction in HAMD-17 at Week 2 (n=201, n=203) | 63 | 41 |
| ≥50% reduction in HAMD-17 at Week 3 (n=202, n=204) | 89 | 53 |
| ≥50% reduction in HAMD-17 at Week 4 (n=202, n=204) | 95 | 74 |
| ≥50% reduction in HAMD-17 at Week 6 (n=202, n=204) | 100 | 81 |
| ≥50% reduction in HAMD-17 at Week 8 (n=202, n=204) | 109 | 84 |
Number of patients who are remitters (defined as patients who achieved a HAMD-17 total score ≤7) at each post-baseline visit.
| Participants | Trazodone Contramid OAD | Placebo |
|---|---|---|
| Number of remitters at Week 1 (n=197, n=199) | 10 | 9 |
| Number of remitters at Week 2 (n=201, n=203) | 29 | 24 |
| Number of remitters at Week 3 (n=202, n=204) | 51 | 32 |
| Number of remitters at Week 4 (n=202, n=204) | 61 | 43 |
| Number of remitters at Week 6 (n=202, n=204) | 66 | 47 |
| Number of remitters at Week 8 (n=202, n=204) | 72 | 65 |
Change from baseline in the HAMD-17, item 1: Depressed Mood item, at each post-baseline visit. The Depressed Mood item is rated on a 5-point scale ranging from rating of 0=absent; to 4=very severe.
| Points on the HAMD scale | Trazodone Contramid OAD | Placebo |
|---|---|---|
| Change in score at Week 1 (n=197, n=199) | -0.7 ± 0.89 | -0.5 ± 0.74 |
| Change in score at Week 2 (n=201, n=203) | -1.1 ± 1.13 | -0.8 ± 0.95 |
| Change in score at Week 3 (n=202, n=204) | -1.4 ± 1.18 | -1.0 ± 1.08 |
| Change in score at Week 4 (n=202, n=204) | -1.5 ± 1.21 | -1.2 ± 1.12 |
| Change in score at Week 6 (n=202, n=204) | -1.5 ± 1.18 | -1.3 ± 1.15 |
| Change in score at Week 8 (n=202, n=204) | -1.6 ± 1.29 | -1.3 ± 1.22 |
The Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10 item clinician-administered depression rating scale. The 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts) are rated on a scale ranging from 0 (low severity/difficulty) to 6 (high severity/difficulty) with anchors at 2-point intervals. The overall total score range is from 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
| Units on MADRS scale | Trazodone Contramid OAD | Placebo |
|---|---|---|
| Baseline (n=202, n=204) | 32.6 ± 4.07 | 31.9 ± 4.33 |
| Week 8 (n=178, n=182) | 16.0 ± 11.24 | 17.7 ± 11.62 |
| Change from baseline (n=178, n=182) | -16.6 ± 11.27 | -14.1 ± 11.27 |
The CGI-Severity (CGI-S) consists of one question for the investigator: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on the following seven-point scale: 1=normal, not ill at all; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.
| Units on CGI-S scale | Trazodone Contramid OAD | Placebo |
|---|---|---|
| Change in CGI-S score at Week 1 (n=197, n=199) | -0.6 ± 0.72 | -0.5 ± 0.75 |
| Change in CGI-S score at Week 2 (n=201, n=203) | -1.0 ± 1.02 | -0.8 ± 0.98 |
| Change in CGI-S score at Week 3 (n=202, n=204) | -1.4 ± 1.16 | -1.1 ± 1.12 |
| Change in CGI-S score at Week 4 (n=202, n=204) | -1.6 ± 1.22 | -1.3 ± 1.17 |
| Change in CGI-S score at Week 6 (n=202, n=204) | -1.7 ± 1.24 | -1.4 ± 1.24 |
| Change in CGI-S score at Week 8 (n=202, n=204) | -1.7 ± 1.36 | -1.4 ± 1.37 |
The CGI-Improvement of Illness (CGI-I) consists of one question for the investigator: "Compared to his condition at the start of the study, how much has this patient changed?" which is rated on the following seven-point scale 1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; 7=very much worse.
| Units on the CGI-I scale | Trazodone Contramid OAD | Placebo |
|---|---|---|
| Clinical Global Impression - Improvement of Illness (CGI-I) Score at Last Study Visit | 2.4 ± 1.23 | 2.5 ± 1.32 |
The PGI-Improvement of Illness (PGI-I) consists of one question for the patient: "Since the start of the study, my overall status with regard to depression is?" which is rated on the following seven-point scale 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6= much worse; 7=very much worse.
| Units on PGI-I scale | Trazodone Contramid OAD | Placebo |
|---|---|---|
| Patient Global Impression - Improvement of Illness (PGI-I) Score at Last Study Visit | 2.6 ± 1.19 | 2.8 ± 1.35 |
Patients were responders if the CGI-I rating was "Much Improved" or "Very Much Improved". The CGI-Improvement of Illness (CGI-I) consists of one question for the investigator: "Compared to his condition at the start of the study, how much has this patient changed?" which is rated on the following seven-point scale 1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; 7=very much worse. Results are expressed in number of patients.
| participants | Trazodone Contramid OAD | Placebo |
|---|---|---|
| Clinical Global Impression - Improvement of Illness (CGI-I) Responders at Last Study Visit | 96 | 89 |
Patients were responders if the PGI-I rating was "Much Improved" or "Very Much Improved". The PGI-Improvement of Illness (PGI-I) consists of one question for the patient: "Since the start of the study, my overall status with regard to depression is?" which is rated on the following seven-point scale 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6= much worse; 7=very much worse. Results are expressed in number of patients.
| participants | Trazodone Contramid OAD | Placebo |
|---|---|---|
| Patient Global Impression - Improvement of Illness (PGI-I) Responders at Last Study Visit | 90 | 80 |
Overall Quality of Sleep was measured on a 4-point rating scale ranging from 1 = very poor to 4 = excellent in response to the question: "Since the last study visit, how would you rate the overall quality of your sleep?".
| Points on a scale | Trazodone Contramid OAD | Placebo |
|---|---|---|
| Score at Baseline (n=202, n=204) | 1.6 ± 0.65 | 1.6 ± 0.70 |
| Score at Week 1 (n=196, n=199) | 0.7 ± 0.90 | 0.4 ± 0.83 |
| Score at Week 2 (n=200, n=203) | 0.8 ± 0.97 | 0.7 ± 0.99 |
| Score at Week 3 (n=201, n=204) | 0.9 ± 1.00 | 0.7 ± 1.00 |
| Score at Week 4 (n=201, n=204) | 1.0 ± 1.02 | 0.7 ± 1.02 |
| Score at Week 6 (n=201, n=204) | 1.0 ± 1.01 | 0.9 ± 1.04 |
| Score at Week 8 (n=201, n=204) | 1.0 ± 1.05 | 0.8 ± 1.10 |
Trouble Falling Asleep was measured on a 4-point rating scale ranging from 1 = never to 4 = always in response to the question: "Since the last study visit, how often did you experience trouble falling asleep?".
| Units on a scale | Trazodone Contramid OAD | Placebo |
|---|---|---|
| Score at Baseline (n=202, n=204) | 3.0 ± 0.86 | 2.9 ± 0.91 |
| Score at Week 1 (n=196, n=199) | 2.5 ± 1.02 | 2.6 ± 0.98 |
| Score at Week 2 (n=200, n=203) | 2.3 ± 0.93 | 2.5 ± 0.96 |
| Score at Week 3 (n=201, n=204) | 2.2 ± 0.90 | 2.3 ± 0.99 |
| Score at Week 4 (n=201, n=204) | 2.1 ± 0.89 | 2.3 ± 0.95 |
| Score at Week 6 (n=201, n=204) | 2.1 ± 0.89 | 2.3 ± 0.95 |
| Score at Week 8 (n=201, n=204) | 2.1 ± 0.85 | 2.3 ± 0.95 |
Awakening during the night was measured on a 4-point rating scale ranging from 1 = never to 4 = always in response to the question: "Since the last study visit did you awaken during the night?".
| Units on a scale | Trazodone Contramid OAD | Placebo |
|---|---|---|
| Score at Baseline (n=202, n=204) | 3.2 ± 0.78 | 3.2 ± 0.78 |
| Score at Week 1 (n=196, n=199) | 2.4 ± 0.96 | 2.7 ± 0.85 |
| Score at Week 2 (n=200, n=203) | 2.4 ± 0.94 | 2.5 ± 0.92 |
| Score at Week 3 (n=201, n=204) | 2.2 ± 0.91 | 2.6 ± 0.90 |
| Score at Week 4 (n=201, n=204) | 2.2 ± 0.89 | 2.6 ± 0.93 |
| Score at Week 6 (n=201, n=204) | 2.2 ± 0.94 | 2.5 ± 0.95 |
| Score at Week 8 (n=201, n=204) | 2.2 ± 0.89 | 2.5 ± 0.95 |
Number of patients who discontinued due to lack of efficacy during the whole study period (8 weeks).
| participants | Trazodone Contramid OAD | Placebo |
|---|---|---|
| Discontinuation Due to Lack of Efficacy | 8 | 9 |
Collected over 8 weeks (plus an additional 30 days for SAEs only). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trazodone Contramid OAD | — | 4/202 (2%) | 168/202 (83.2%) |
| Placebo | — | 2/204 (1%) | 122/204 (59.8%) |
| Event | Trazodone Contramid OAD | Placebo |
|---|---|---|
| Abdominal painGastrointestinal disorders | 1/202 | 0/204 |
| Duodenal ulcerGastrointestinal disorders | 1/202 | 0/204 |
| GastritisGastrointestinal disorders | 1/202 | 0/204 |
| Staphylococcal sepsisInfections and infestations | 1/202 | 0/204 |
| Viral pericarditisInfections and infestations | 1/202 | 0/204 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/202 | 0/204 |
| DeathGeneral disorders | 0/202 | 1/204 |
| Suicide attemptPsychiatric disorders | 0/202 | 1/204 |
| Event | Trazodone Contramid OAD | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 67/202 | 55/204 |
| SomnolenceNervous system disorders | 63/202 | 32/204 |
| Dry mouthGastrointestinal disorders | 51/202 | 26/204 |
| DizzinessNervous system disorders | 50/202 | 25/204 |
| NauseaGastrointestinal disorders | 42/202 | 26/204 |
| SedationNervous system disorders | 34/202 | 7/204 |
| FatigueGeneral disorders | 30/202 | 17/204 |
| DiarrheaGastrointestinal disorders | 19/202 | 23/204 |
| ConstipationGastrointestinal disorders | 16/202 | 4/204 |
| Vision blurredEye disorders | 11/202 | 0/204 |
| Age, Categorical(Participants) | Trazodone Contramid OAD | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 2 | 2 |
| Between 18 and 65 years | 193 | 186 | 379 |
| >=65 years | 9 | 16 | 25 |
| Age Continuous(years) | Trazodone Contramid OAD | Placebo | Total |
|---|---|---|---|
| Mean | 43.8 ± 12.83 | 44.0 ± 13.45 | 43.9 ± 13.12 |
| Sex: Female, Male(Participants) | Trazodone Contramid OAD | Placebo | Total |
|---|---|---|---|
| Female | 129 | 131 | 260 |
| Male | 73 | 73 | 146 |
| Region of Enrollment(participants) | Trazodone Contramid OAD | Placebo | Total |
|---|---|---|---|
| United States | 169 | 166 | 335 |
| Canada | 33 | 38 | 71 |
The record gives a start of Jun 2007, a primary completion of Nov 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2010, 2 years 5 months after primary completion. A results delay was requested in Mar 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trazodone
Labopharm Inc.